Statins in the 21st century: end of the simple story?

被引:25
作者
Doggrell, SA [1 ]
机构
[1] Doggrell Biomed Commun, Auckland, New Zealand
关键词
clinical trials; lipid-lowering; mechanisms; statins;
D O I
10.1517/13543784.10.9.1755
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The development of the HMG-CoA reductase inhibitors (the statins) has lead to important advances in the management of cardiovascular disease. There have several landmark mortality and morbidity clinical trials with the statins. The 4S (Scandinavian Simvastatin Survival Study) was the first large-scale randomised cholesterol-lowering trial to show a decrease in mortality. In patients with coronary heart disease and relatively high cholesterol, simvastatin decreased mortality, hospital stays, the risk of undergoing myocardial revascularisation, stroke and transient ischaemic attack. The CARE (Cholesterol and Recurrent Events) trial showed that lowering average cholesterol levels after myocardial infarction with pravastatin reduced a composite primary end point of coronary mortality and myocardial infarction, coronary bypass surgery, angioplasty and strokes. The LIPID (Long-term Intervention with Pravastatin in Ischaaemic Disease) study showed that lowering average cholesterol levels after previous myocardial infarction or unstable angina reduced mortality. WOSCOPS (The West of Scotland Coronary Prevention Study) was the first trial to demonstrate the benefit of pravastatin, as primary prevention for cardiovascular disease, in men with high cholesterol levels. AFCAPS/Tex CAPS (The Air Force/Texas Coronary Atherosclerosis Prevention Study) showed that the benefits of lowering cholesterol levels were also evident in healthy men and women who initially had average cholesterol levels. Rather surprisingly the reductions in mortality and morbidity with statins are only associated with small improvements in coronary angiographic findngs. A preliminary study indicated than lovastatin prevented restenosis, but larger and better-controlled studies indicate that the statins do not have beneficial effects in restenosis. Effects other than lipid-lowering or as a consequence of their lipid-lowering may contribute to the beneficial effects of statins. These effects include improvement in vascular endothelial function, cardiac remodelling, changes in blood rheology, anti-oxidant, anti-inflammatory and antihypertensive actions.
引用
收藏
页码:1755 / 1766
页数:12
相关论文
共 74 条
[1]   The Pravastatin Inflammation CRP Evaluation (PRINCE): Rationale and design [J].
Albert, MA ;
Staggers, J ;
Chew, P ;
Ridker, PM .
AMERICAN HEART JOURNAL, 2001, 141 (06) :893-898
[2]   An evidence-based assessment of the NCEP Adult Treatment Panel II guidelines [J].
Ansell, BJ ;
Watson, KE ;
Fogelman, AM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (21) :2051-2057
[3]   Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty [J].
Bertrand, ME ;
McFadden, EP ;
Fruchart, JC ;
VanBelle, E ;
Commeau, P ;
Grollier, G ;
Bassand, JP ;
Machecourt, J ;
Cassagnes, J ;
Mossard, JM ;
Vacheron, A ;
Castaigne, A ;
Danchin, N ;
Lablanche, JM .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1997, 30 (04) :863-869
[4]  
Bestehorn HP, 1997, EUR HEART J, V18, P226
[5]   CORONARY ANGIOGRAPHIC CHANGES WITH LOVASTATIN THERAPY - THE MONITORED ATHEROSCLEROSIS REGRESSION STUDY (MARS) [J].
BLANKENHORN, DH ;
AZEN, SP ;
KRAMSCH, DM ;
MACK, WJ ;
CASHINHEMPHILL, L ;
HODIS, HN ;
DEBOER, LWV ;
MAHRER, PR ;
MASTELLER, MJ ;
VAILAS, LI ;
ALAUPOVIC, P ;
HIRSCH, LJ .
ANNALS OF INTERNAL MEDICINE, 1993, 119 (10) :969-976
[6]   Stroke, statins, and cholesterol - A meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors [J].
Blauw, GJ ;
Lagaay, AM ;
Smelt, AHM ;
Westendorp, RGJ .
STROKE, 1997, 28 (05) :946-950
[7]   REGRESSION OF CORONARY-ARTERY DISEASE AS A RESULT OF INTENSIVE LIPID-LOWERING THERAPY IN MEN WITH HIGH-LEVELS OF APOLIPOPROTEIN-B [J].
BROWN, G ;
ALBERS, JJ ;
FISHER, LD ;
SCHAEFER, SM ;
LIN, JT ;
KAPLAN, C ;
ZHAO, XQ ;
BISSON, BD ;
FITZPATRICK, VF ;
DODGE, HT .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 323 (19) :1289-1298
[8]   Aggressive cholesterol lowering delays saphenous vein graft atherosclerosis in women, the elderly, and patients with associated risk factors - NHLBI post coronary artery bypass graft clinical trial [J].
Campeau, L ;
Hunninghake, DB ;
Knatterud, GL ;
White, CW ;
Domanski, M ;
Forman, SA ;
Forrester, JS ;
Geller, NL ;
Gobel, FL ;
Herd, JA ;
Hoogwerf, BJ ;
Rosenberg, Y .
CIRCULATION, 1999, 99 (25) :3241-3247
[9]  
Campeau L, 1997, NEW ENGL J MED, V336, P153
[10]  
CARLOS TM, 1994, BLOOD, V84, P2068